BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 2011;13:806-19. [PMID: 21757446 DOI: 10.1093/neuonc/nor054] [Cited by in Crossref: 180] [Cited by in F6Publishing: 163] [Article Influence: 16.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Hu X, Xie P, Li W, Li X, Ma L. Comparison of magnetic resonance spectroscopy and positron emission tomography in detection of tumor recurrence in posttreatment of glioma: A diagnostic meta-analysis. Asia Pac J Clin Oncol 2015;11:97-105. [PMID: 24783970 DOI: 10.1111/ajco.12202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
2 Seifert R, Weber M, Kocakavuk E, Rischpler C, Kersting D. Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives. Semin Nucl Med 2021;51:170-7. [PMID: 33509373 DOI: 10.1053/j.semnuclmed.2020.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
3 Laukamp KR, Lindemann F, Weckesser M, Hesselmann V, Ligges S, Wölfer J, Jeibmann A, Zinnhardt B, Viel T, Schäfers M, Paulus W, Stummer W, Schober O, Jacobs AH. Multimodal Imaging of Patients With Gliomas Confirms 11C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy. Mol Imaging 2017;16:1536012116687651. [PMID: 28654379 DOI: 10.1177/1536012116687651] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
4 Omay SB, Piepmeier JM, Knisely JP. Low-grade gliomas: when and how to treat. Hematol Oncol Clin North Am 2012;26:797-809. [PMID: 22794284 DOI: 10.1016/j.hoc.2012.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Hassanzadeh C, Rao YJ, Chundury A, Rowe J, Ponisio MR, Sharma A, Miller-Thomas M, Tsien CI, Ippolito JE. Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma. Front Oncol 2017;7:178. [PMID: 28868256 DOI: 10.3389/fonc.2017.00178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Unterrainer M, Schweisthal F, Suchorska B, Wenter V, Schmid-Tannwald C, Fendler WP, Schüller U, Bartenstein P, Tonn JC, Albert NL. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense? J Nucl Med 2016;57:1177-82. [PMID: 27033893 DOI: 10.2967/jnumed.115.171033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
7 Wang Z, Zhang M, Wang L, Wang S, Kang F, Li G, Jacobson O, Niu G, Yang W, Wang J, Chen X. Prospective Study of (68)Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients. Theranostics 2015;5:882-9. [PMID: 26000059 DOI: 10.7150/thno.12303] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
8 Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget 2016;7:34942-55. [PMID: 27144334 DOI: 10.18632/oncotarget.9006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
9 Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougère C, Schmidt NO, Tonn JC, Vogelbaum MA, Wen PY, Aldape K, Nassiri F, Zadeh G, Dunn IF; International Consortium on Meningiomas. Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol 2019;21:i44-61. [PMID: 30649491 DOI: 10.1093/neuonc/noy143] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
10 Aldalilah Y, Fraioli F, Bomanji J. Neuro-oncology tracers: an already limited supply impacted by the pandemic? Nucl Med Commun 2020;41:1223-5. [PMID: 32956250 DOI: 10.1097/MNM.0000000000001294] [Reference Citation Analysis]
11 Schwartz C, Romagna A, Thon N, Niyazi M, Watson J, Belka C, Tonn JC, Kreth FW, Nachbichler SB. Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas. Acta Neurochir (Wien) 2015;157:1757-64; discussion 1764. [PMID: 26298594 DOI: 10.1007/s00701-015-2550-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Laudicella R, Bauckneht M, Cuppari L, Donegani MI, Arnone A, Baldari S, Burger IA, Quartuccio N; Young Italian Association of Nuclear Medicine (AIMN) Group. Emerging applications of imaging in glioma: focus on PET/MRI and radiomics. Clin Transl Imaging 2021;9:609-23. [DOI: 10.1007/s40336-021-00464-7] [Reference Citation Analysis]
13 Villena Martín M, Pena Pardo FJ, Jiménez Aragón F, Borras Moreno JM, García Vicente AM. Metabolic targeting can improve the efficiency of brain tumor biopsies. Seminars in Oncology 2020;47:148-54. [DOI: 10.1053/j.seminoncol.2020.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Buck JR, McKinley ET, Fu A, Abel TW, Thompson RC, Chambless L, Watchmaker JM, Harty JP, Cooper MK, Manning HC. Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study. PLoS One 2015;10:e0141659. [PMID: 26517124 DOI: 10.1371/journal.pone.0141659] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
15 Mohammadzadeh A, Mohammadzadeh V, Kooraki S, Sotoudeh H, Kadivar S, Shakiba M, Rasuli B, Borhani A, Mohammadzadeh M. Pretreatment Evaluation of Glioma. Neuroimaging Clinics of North America 2016;26:567-80. [DOI: 10.1016/j.nic.2016.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, Galldiks N, Steinbach JP, Hattingen E, Langen KJ. 18F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience. J Nucl Med 2020;61:505-11. [PMID: 31519802 DOI: 10.2967/jnumed.119.234757] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Bisdas S, lá Fougere C, Ernemann U. Hybrid MR-PET in Neuroimaging. Clin Neuroradiol 2015;25:275-81. [DOI: 10.1007/s00062-015-0427-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Lopez WO, Cordeiro JG, Albicker U, Doostkam S, Nikkhah G, Kirch RD, Trippel M, Reithmeier T. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther 2015;8:3803-15. [PMID: 26719708 DOI: 10.2147/OTT.S87126] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
19 Kim BYS, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. J Neurooncol 2014;118:405-12. [PMID: 24777756 DOI: 10.1007/s11060-014-1451-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
20 Gupta M, Choudhury PS, Premsagar IC, Gairola M, Ahlawat P. Role of 68Ga-Prostate-Specific Membrane Antigen PET/CT in Disease Assessment in Glioblastoma Within 48 Hours of Surgery. Clin Nucl Med 2020;45:204-5. [PMID: 31977462 DOI: 10.1097/RLU.0000000000002893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ly KI, Gerstner ER. The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies. Curr Treat Options Oncol 2018;19:40. [PMID: 29931476 DOI: 10.1007/s11864-018-0558-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Chambers G, Frood R, Patel C, Scarsbrook A. 18F-FDG PET-CT in paediatric oncology: established and emerging applications. Br J Radiol 2019;92:20180584. [PMID: 30383441 DOI: 10.1259/bjr.20180584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Belykh E, Shaffer KV, Lin C, Byvaltsev VA, Preul MC, Chen L. Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors. Front Oncol 2020;10:739. [PMID: 32582530 DOI: 10.3389/fonc.2020.00739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
24 Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, Qiu X, Wang W, Li W, Yao Y, Li S, Li S, Wu A, Sai K, Bai H, Li G, Chen B, Yao K, Wei X, Liu X, Zhang Z, Dai Y, Lv S, Wang L, Lin Z, Dong J, Xu G, Ma X, Cai J, Zhang W, Wang H, Chen L, Zhang C, Yang P, Yan W, Liu Z, Hu H, Chen J, Liu Y, Yang Y, Wang Z, Wang Z, Wang Y, You G, Han L, Bao Z, Liu Y, Wang Y, Fan X, Liu S, Liu X, Wang Y, Wang Q; Chinese Glioma Cooperative Group (CGCG). CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 2016;375:263-73. [PMID: 26966000 DOI: 10.1016/j.canlet.2016.01.024] [Cited by in Crossref: 193] [Cited by in F6Publishing: 201] [Article Influence: 32.2] [Reference Citation Analysis]
25 Zhang Q, Gao X, Wei G, Qiu C, Qu H, Zhou X. Prognostic Value of MTV, SUVmax and the T/N Ratio of PET/CT in Patients with Glioma: A Systematic Review and Meta-Analysis. J Cancer 2019;10:1707-16. [PMID: 31205526 DOI: 10.7150/jca.28605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
26 Lim TX, Ahamed M, Reutens DC. The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma. Drug Discov Today 2021:S1359-6446(21)00427-X. [PMID: 34624509 DOI: 10.1016/j.drudis.2021.09.021] [Reference Citation Analysis]
27 Puranik AD, Boon M, Purandare N, Rangarajan V, Gupta T, Moiyadi A, Shetty P, Sridhar E, Agrawal A, Dev I, Shah S. Utility of FET-PET in detecting high-grade gliomas presenting with equivocal MR imaging features. World J Nucl Med 2019;18:266-72. [PMID: 31516370 DOI: 10.4103/wjnm.WJNM_89_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Tonn JC, Thon N, Schnell O, Kreth FW. Personalized surgical therapy. Ann Oncol 2012;23 Suppl 10:x28-32. [PMID: 22987977 DOI: 10.1093/annonc/mds363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
29 Lei W, Zeng H, Zeng DX, Zhang B, Zhu YH, Jiang JH, Huang JA. (18)F-FDG PET-CT: a powerful tool for the diagnosis and treatment of relapsing polychondritis. Br J Radiol 2016;89:20150695. [PMID: 26529231 DOI: 10.1259/bjr.20150695] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
30 Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S. Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines 2016;4:E24. [PMID: 28536391 DOI: 10.3390/biomedicines4040024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
31 Sepehrizadeh T, Jong I, DeVeer M, Malhotra A. PET/MRI in paediatric disease. Eur J Radiol 2021;144:109987. [PMID: 34649143 DOI: 10.1016/j.ejrad.2021.109987] [Reference Citation Analysis]
32 Tripathi SK, Kean R, Bongiorno E, Hooper DC, Jin YY, Wickstrom E, McCue PA, Thakur ML. Targeting VPAC1 Receptors for Imaging Glioblastoma. Mol Imaging Biol 2020;22:293-302. [PMID: 31292914 DOI: 10.1007/s11307-019-01388-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Holzgreve A, Albert NL, Galldiks N, Suchorska B. Use of PET Imaging in Neuro-Oncological Surgery. Cancers (Basel) 2021;13:2093. [PMID: 33926002 DOI: 10.3390/cancers13092093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Saade-lemus S, Teixeira SR, Vossough A, Servaes S, States LJ. Emerging Roles of PET/MR in the Pediatric Hospital. PET Clinics 2020;15:253-69. [DOI: 10.1016/j.cpet.2020.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Sipos D, László Z, Tóth Z, Kovács P, Tollár J, Gulybán A, Lakosi F, Repa I, Kovács A. Additional Value of 18F-FDOPA Amino Acid Analog Radiotracer to Irradiation Planning Process of Patients With Glioblastoma Multiforme. Front Oncol 2021;11:699360. [PMID: 34295825 DOI: 10.3389/fonc.2021.699360] [Reference Citation Analysis]
36 Pronin AI, Dolgushin MB, Lyuosev AS, Odzharova AA, Nevzorov DI, Nechipay EA, Gasparyan TG. Capabilities of 18F-FET PET/CT in a patient with brain glioma (a case report and literature review). Vopr neirokhir 2018;82:95. [DOI: 10.17116/oftalma201882295-99] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol 2016;18:426-34. [PMID: 26243791 DOI: 10.1093/neuonc/nov148] [Cited by in Crossref: 93] [Cited by in F6Publishing: 71] [Article Influence: 13.3] [Reference Citation Analysis]
38 Wilson TW, Heinrichs-Graham E, Aizenberg MR. Potential role for magnetoencephalography in distinguishing low- and high-grade gliomas: a preliminary study with histopathological confirmation. Neuro Oncol 2012;14:624-30. [PMID: 22447561 DOI: 10.1093/neuonc/nos064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 Faria G, Silva E, Da Fonseca C, Quirico-Santos T. Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy. Int J Mol Sci 2018;19:E1610. [PMID: 29848970 DOI: 10.3390/ijms19061610] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
40 Ma H, Zhao J, Liu S, Xie D, Zhang Z, Nie D, Wen F, Yang Z, Tang G. 18F-Trifluoromethylated D-Cysteine as a Promising New PET Tracer for Glioma Imaging: Comparative Analysis With MRI and Histopathology in Orthotopic C6 Models. Front Oncol 2021;11:645162. [PMID: 33996562 DOI: 10.3389/fonc.2021.645162] [Reference Citation Analysis]
41 Chavda V, Patel V, Yadav D, Shah J, Patel S, Jin J. Therapeutics and Research Related to Glioblastoma: Advancements and Future Targets. CDM 2020;21:186-98. [DOI: 10.2174/1389200221666200408083950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn JC, Bartenstein P, Kreth FW, la Fougère C. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med 2015;56:9-15. [PMID: 25537990 DOI: 10.2967/jnumed.114.144675] [Cited by in Crossref: 106] [Cited by in F6Publishing: 89] [Article Influence: 15.1] [Reference Citation Analysis]
43 Wu SK, Tsai CL, Hynynen K. Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective. Handb Exp Pharmacol 2021. [PMID: 33454856 DOI: 10.1007/164_2020_408] [Reference Citation Analysis]
44 Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, Wang J, Kang P, Liu Z, Shi J, Chen X, Zhu Z. (68)Ga-PRGD2 PET/CT in the evaluation of Glioma: a prospective study. Mol Pharm 2014;11:3923-9. [PMID: 25093246 DOI: 10.1021/mp5003224] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
45 Domenech Brasero B, Mestre-Fusco A, Suárez Piñera M, Puertas Calvo E, Perich Alsina X, Montes G, Plaza López P. Preliminary evaluation of cerebral 18F-DOPA PET/CT in the differential diagnosis of brain lesions in inconclusive MR. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:214-21. [PMID: 34218883 DOI: 10.1016/j.remnie.2020.10.011] [Reference Citation Analysis]
46 John F, Bosnyák E, Robinette NL, Amit-Yousif AJ, Barger GR, Shah KD, Michelhaugh SK, Klinger NV, Mittal S, Juhász C. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival. Neuro Oncol 2019;21:264-73. [PMID: 30346623 DOI: 10.1093/neuonc/noy169] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
47 Ertl-Wagner B, Ingrisch M, Niyazi M, Schnell O, Jansen N, Förster S, la Fougère C. [PET-MR in patients with glioblastoma multiforme]. Radiologe 2013;53:682-90. [PMID: 23949437 DOI: 10.1007/s00117-013-2500-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
48 Saadatpour Z, Bjorklund G, Chirumbolo S, Alimohammadi M, Ehsani H, Ebrahiminejad H, Pourghadamyari H, Baghaei B, Mirzaei HR, Sahebkar A, Mirzaei H, Keshavarzi M. Molecular imaging and cancer gene therapy. Cancer Gene Ther. [DOI: 10.1038/cgt.2016.62] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
49 Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Drexler M, Bartenstein P, Schnell O, Tonn JC, Thon N, Kreth FW, la Fougère C. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 2014;55:198-203. [PMID: 24379223 DOI: 10.2967/jnumed.113.122333] [Cited by in Crossref: 101] [Cited by in F6Publishing: 83] [Article Influence: 11.2] [Reference Citation Analysis]
50 Berntsson SG, Falk A, Savitcheva I, Godau A, Zetterling M, Hesselager G, Alafuzoff I, Larsson EM, Smits A. Perfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas. J Neurooncol 2013;114:241-9. [PMID: 23771511 DOI: 10.1007/s11060-013-1178-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
51 Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol 2016;134:381-97. [PMID: 26948367 DOI: 10.1016/B978-0-12-802997-8.00023-2] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 18.0] [Reference Citation Analysis]
52 Lawton CD, Nagasawa DT, Yang I, Fessler RG, Smith ZA. Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease: A review. SPI 2012;17:438-48. [DOI: 10.3171/2012.7.spine12212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
53 Tran DK, Jensen RL. Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities. Surg Neurol Int 2013;4:S129-35. [PMID: 23682339 DOI: 10.4103/2152-7806.110661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
54 Riva M, Lopci E, Gay LG, Nibali MC, Rossi M, Sciortino T, Castellano A, Bello L. Advancing Imaging to Enhance Surgery: From Image to Information Guidance. Neurosurg Clin N Am 2021;32:31-46. [PMID: 33223024 DOI: 10.1016/j.nec.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Fleischmann DF, Unterrainer M, Schön R, Corradini S, Maihöfer C, Bartenstein P, Belka C, Albert NL, Niyazi M. Margin reduction in radiotherapy for glioblastoma through 18F-fluoroethyltyrosine PET? - A recurrence pattern analysis. Radiother Oncol 2020;145:49-55. [PMID: 31923709 DOI: 10.1016/j.radonc.2019.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
56 Oehlke O, Grosu A. PET/MRI and brain tumors: focus on radiation oncology treatment planning. Clin Transl Imaging 2017;5:159-67. [DOI: 10.1007/s40336-016-0206-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Tanaka K, Yamamoto Y, Maeda Y, Yamamoto H, Kudomi N, Kawai N, Toyohara J, Nishiyama Y. Correlation of 4’-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake. Ann Nucl Med. 2016;30:89-96. [PMID: 26511019 DOI: 10.1007/s12149-015-1035-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
58 Nikaki A, Angelidis G, Efthimiadou R, Tsougos I, Valotassiou V, Fountas K, Prasopoulos V, Georgoulias P. 18F-fluorothymidine PET imaging in gliomas: an update. Ann Nucl Med 2017;31:495-505. [PMID: 28612247 DOI: 10.1007/s12149-017-1183-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
59 Dunet V, Prior JO. Diagnostic accuracy of F-18-fluoroethyltyrosine PET and PET/CT in patients with brain tumor. Clin Transl Imaging 2013;1:135-44. [DOI: 10.1007/s40336-013-0017-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Jarzabek MA, Sweeney KJ, Evans RL, Jacobs AH, Stupp R, O’brien D, Berger MS, Prehn JH, Byrne AT. Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. Drug Discovery Today 2013;18:1052-66. [DOI: 10.1016/j.drudis.2013.06.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
61 Morana G, Piccardo A, Puntoni M, Nozza P, Cama A, Raso A, Mascelli S, Massollo M, Milanaccio C, Garrè ML, Rossi A. Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study. Neuro Oncol 2015;17:1637-47. [PMID: 26405202 DOI: 10.1093/neuonc/nov099] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
62 Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med 2013;54:90-5. [PMID: 23236019 DOI: 10.2967/jnumed.112.109777] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
63 Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics 2019;9:5085-104. [PMID: 31410203 DOI: 10.7150/thno.34415] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
64 Belloli S, Brioschi A, Politi LS, Ronchetti F, Calderoni S, Raccagni I, Pagani A, Monterisi C, Zenga F, Zara G. Characterization of biological features of a rat F98 GBM model: a PET-MRI study with [18F]FAZA and [18F]FDG. Nucl Med Biol. 2013;40:831-840. [PMID: 23915802 DOI: 10.1016/j.nucmedbio.2013.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
65 Pippin AB, Voll RJ, Li Y, Wu H, Mao H, Goodman MM. Radiochemical Synthesis and Evaluation of 13N-Labeled 5-Aminolevulinic Acid for PET Imaging of Gliomas. ACS Med Chem Lett 2017;8:1236-40. [PMID: 29259740 DOI: 10.1021/acsmedchemlett.7b00311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
66 Xiao J, Jin Y, Nie J, Chen F, Ma X. Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis. BMC Cancer 2019;19:767. [PMID: 31382920 DOI: 10.1186/s12885-019-5938-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
67 Ruff M, Kizilbash S, Buckner J. Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. Expert Rev Anticancer Ther 2020;20:355-63. [PMID: 32301635 DOI: 10.1080/14737140.2020.1757440] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Viswanath P, Batsios G, Ayyappan V, Taglang C, Gillespie AM, Larson PEZ, Luchman HA, Costello JF, Pieper RO, Ronen SM. Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas. Neuro Oncol 2021:noab093. [PMID: 33864084 DOI: 10.1093/neuonc/noab093] [Reference Citation Analysis]
69 Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, Lutz J, Egensperger R, Giese A, Herms J, Weller M, Kretzschmar H, Tonn JC, la Fougère C, Kreth FW. Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. Int J Cancer 2015;136:2132-45. [PMID: 25311315 DOI: 10.1002/ijc.29259] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
70 Cui M, Zorrilla-Veloz RI, Hu J, Guan B, Ma X. Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis. Front Neurol 2021;12:671867. [PMID: 34093419 DOI: 10.3389/fneur.2021.671867] [Reference Citation Analysis]
71 Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR Am J Roentgenol 2013;200:W654-60. [PMID: 23701099 DOI: 10.2214/AJR.12.9168] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
72 Dissaux G, Basse V, Schick U, El Kabbaj O, Auberger B, Magro E, Kassoul A, Abgral R, Salaun PY, Bourhis D, Querellou S. Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma. Medicine (Baltimore) 2020;99:e19017. [PMID: 32000446 DOI: 10.1097/MD.0000000000019017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Gatidis S, Bender B, Reimold M, Schäfer JF. PET/MRI in children. European Journal of Radiology 2017;94:A64-70. [DOI: 10.1016/j.ejrad.2017.01.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
74 Kurbegovic S, Juhl K, Sørensen KK, Leth J, Willemoe GL, Christensen A, Adams Y, Jensen AR, von Buchwald C, Skjøth-Rasmussen J, Ploug M, Jensen KJ, Kjaer A. IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts. Theranostics 2021;11:7159-74. [PMID: 34158842 DOI: 10.7150/thno.49787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Vaidya T, Agrawal A, Mahajan S, Thakur MH, Mahajan A. The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part I). Mol Diagn Ther 2019;23:1-26. [PMID: 30411216 DOI: 10.1007/s40291-018-0366-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
76 Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y, Maesawa S, Takebayashi S, Wakabayashi T, Naganawa S. Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system. Ann Nucl Med 2014;28:94-102. [PMID: 24272066 DOI: 10.1007/s12149-013-0787-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
77 Vieira DB, Gamarra LF. Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. Int J Nanomedicine 2016;11:5381-414. [PMID: 27799765 DOI: 10.2147/IJN.S117210] [Cited by in Crossref: 155] [Cited by in F6Publishing: 64] [Article Influence: 25.8] [Reference Citation Analysis]
78 Saga I, Shibao S, Okubo J, Osuka S, Kobayashi Y, Yamada S, Fujita S, Urakami K, Kusuhara M, Yoshida K, Saya H, Sampetrean O. Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model. Neuro Oncol 2014;16:1048-56. [PMID: 24860177 DOI: 10.1093/neuonc/nou096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
79 Liu FM, Gao YF, Kong Y, Guan Y, Zhang J, Li SH, Ye D, Wen W, Zuo C, Hua W. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET. BMC Cancer 2021;21:83. [PMID: 33472598 DOI: 10.1186/s12885-021-07797-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. Nat Rev Dis Primers 2015;1:15017. [PMID: 27188790 DOI: 10.1038/nrdp.2015.17] [Cited by in Crossref: 247] [Cited by in F6Publishing: 257] [Article Influence: 35.3] [Reference Citation Analysis]
81 Halle B, Thisgaard H, Hvidsten S, Dam JH, Aaberg-Jessen C, Thykjær AS, Høilund-Carlsen PF, Schulz MK, Andersen C, Kristensen BW. Estimation of Tumor Volumes by 11C-MeAIB and 18F-FDG PET in an Orthotopic Glioblastoma Rat Model. J Nucl Med 2015;56:1562-8. [PMID: 26229144 DOI: 10.2967/jnumed.115.162511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
82 Jung JH, Ahn BC. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat 2018;6:47-53. [PMID: 30381916 DOI: 10.14791/btrt.2018.6.e13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
83 Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 2012;53:207-14. [PMID: 22302961 DOI: 10.2967/jnumed.111.096859] [Cited by in Crossref: 161] [Cited by in F6Publishing: 124] [Article Influence: 16.1] [Reference Citation Analysis]
84 Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-tannwald C, Mille E, Todica A, Brendel M, Tonn J, Bartenstein P, la Fougère C. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging 2016;43:1105-14. [DOI: 10.1007/s00259-015-3276-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
85 Anderson MD, Colen RR, Tremont-lukats IW. Imaging Mimics of Primary Malignant Tumors of the Central Nervous System (CNS). Curr Oncol Rep 2014;16. [DOI: 10.1007/s11912-014-0399-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
86 Gkika E, Oehlke O, Bunea H, Wiedenmann N, Adebahr S, Nestle U, Zamboglou C, Kirste S, Fennell J, Brunner T, Gainey M, Baltas D, Langer M, Urbach H, Bock M, Meyer PT, Grosu A. Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncology 2018;14:751-69. [DOI: 10.2217/fon-2017-0465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
87 Laudicella R, Quartuccio N, Argiroffi G, Alongi P, Baratto L, Califaretti E, Frantellizzi V, De Vincentis G, Del Sole A, Evangelista L, Baldari S, Bisdas S, Ceci F, Iagaru A; Young Italian Association of Nuclear Medicine (AIMN) group. Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas. Eur J Nucl Med Mol Imaging 2021. [PMID: 33851243 DOI: 10.1007/s00259-021-05352-w] [Reference Citation Analysis]
88 Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 2013;34:944-50, S1-11. [PMID: 23124638 DOI: 10.3174/ajnr.A3324] [Cited by in Crossref: 102] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
89 Jeong JW, Juhász C, Mittal S, Bosnyák E, Kamson DO, Barger GR, Robinette NL, Kupsky WJ, Chugani DC. Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas. Cancer Imaging 2015;15:10. [PMID: 26245742 DOI: 10.1186/s40644-015-0045-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
90 Romagna A, Schwartz C, Egensperger R, Watson J, Tonn JC, Belka C, Kreth FW, Nachbichler SB. Iodine-125 brachytherapy as upfront and salvage treatment for brain metastases : A comparative analysis. Strahlenther Onkol 2016;192:780-8. [PMID: 27349709 DOI: 10.1007/s00066-016-1009-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
91 Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016;18:1199-208. [PMID: 27106405 DOI: 10.1093/neuonc/now058] [Cited by in Crossref: 336] [Cited by in F6Publishing: 275] [Article Influence: 56.0] [Reference Citation Analysis]
92 Heiss WD. Hybrid PET/MR Imaging in Neurology: Present Applications and Prospects for the Future. J Nucl Med 2016;57:993-5. [PMID: 27056615 DOI: 10.2967/jnumed.116.175208] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
93 Dunet V, Maeder P, Nicod-Lalonde M, Lhermitte B, Pollo C, Bloch J, Stupp R, Meuli R, Prior JO. Combination of MRI and dynamic FET PET for initial glioma grading. Nuklearmedizin 2014;53:155-61. [PMID: 24737132 DOI: 10.3413/Nukmed-0650-14-03] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
94 Werner P, Barthel H, Drzezga A, Sabri O. Current status and future role of brain PET/MRI in clinical and research settings. Eur J Nucl Med Mol Imaging 2015;42:512-26. [PMID: 25573629 DOI: 10.1007/s00259-014-2970-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 34] [Article Influence: 7.7] [Reference Citation Analysis]
95 Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougère C. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 2012;39:1021-9. [PMID: 22491781 DOI: 10.1007/s00259-012-2109-9] [Cited by in Crossref: 120] [Cited by in F6Publishing: 101] [Article Influence: 12.0] [Reference Citation Analysis]
96 Larsen VA, Simonsen HJ, Law I, Larsson HB, Hansen AE. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology 2013;55:361-9. [PMID: 23262559 DOI: 10.1007/s00234-012-1127-4] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 7.5] [Reference Citation Analysis]
97 Mitamura K, Yamamoto Y, Kudomi N, Maeda Y, Norikane T, Miyake K, Nishiyama Y. Intratumoral heterogeneity of 18F-FLT uptake predicts proliferation and survival in patients with newly diagnosed gliomas. Ann Nucl Med 2017;31:46-52. [PMID: 27686469 DOI: 10.1007/s12149-016-1129-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
98 Petridis PD, Horenstein C, Pereira B, Wu P, Samanamud J, Marie T, Boyett D, Sudhakar T, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Canoll P, Grinband J. BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas. Neuro Oncol 2021:noab154. [PMID: 34214170 DOI: 10.1093/neuonc/noab154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Karlberg A, Berntsen EM, Johansen H, Skjulsvik AJ, Reinertsen I, Dai HY, Xiao Y, Rivaz H, Borghammer P, Solheim O, Eikenes L. 18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas. Clin Nucl Med 2019;44:550-9. [PMID: 31107743 DOI: 10.1097/RLU.0000000000002610] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
100 Yu P, Ning J, Xu B, Liu J, Dang H, Lin M, Feng X, Grimm R, Tian J. Histogram analysis of 11C-methionine integrated PET/MRI may facilitate to determine the O6-methylguanylmethyltransferase methylation status in gliomas. Nucl Med Commun 2019;40:850-6. [PMID: 31135693 DOI: 10.1097/MNM.0000000000001039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
101 Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J Biomed Biotechnol 2012;2012:205818. [PMID: 22577290 DOI: 10.1155/2012/205818] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
102 Takashima H, Tsuji AB, Saga T, Yasunaga M, Koga Y, Kuroda JI, Yano S, Kuratsu JI, Matsumura Y. Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep. 2017;7:12341. [PMID: 28951589 DOI: 10.1038/s41598-017-12563-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
103 Kasten BB, Jiang K, Cole D, Jani A, Udayakumar N, Gillespie GY, Lu G, Dai T, Rosenthal EL, Markert JM, Rao J, Warram JM. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. Eur J Nucl Med Mol Imaging 2020;47:1412-26. [PMID: 31773232 DOI: 10.1007/s00259-019-04607-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
104 Rudà R, Angileri FF, Ius T, Silvani A, Sarubbo S, Solari A, Castellano A, Falini A, Pollo B, Del Basso De Caro M, Papagno C, Minniti G, De Paula U, Navarria P, Nicolato A, Salmaggi A, Pace A, Fabi A, Caffo M, Lombardi G, Carapella CM, Spena G, Iacoangeli M, Fontanella M, Germanò AF, Olivi A, Bello L, Esposito V, Skrap M, Soffietti R; SINch Neuro-Oncology Section, AINO and SIN Neuro-Oncology Section. Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. J Neurosurg Sci 2020;64:313-34. [PMID: 32347684 DOI: 10.23736/S0390-5616.20.04982-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
105 Shen N, Zhang S, Cho J, Li S, Zhang J, Xie Y, Wang Y, Zhu W. Application of Cluster Analysis of Time Evolution for Magnetic Resonance Imaging -Derived Oxygen Extraction Fraction Mapping: A Promising Strategy for the Genetic Profile Prediction and Grading of Glioma. Front Neurosci 2021;15:736891. [PMID: 34671241 DOI: 10.3389/fnins.2021.736891] [Reference Citation Analysis]
106 Blanc-Durand P, Van Der Gucht A, Schaefer N, Itti E, Prior JO. Automatic lesion detection and segmentation of 18F-FET PET in gliomas: A full 3D U-Net convolutional neural network study. PLoS One 2018;13:e0195798. [PMID: 29652908 DOI: 10.1371/journal.pone.0195798] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
107 Yang Y, Chen J, Yang Y, Xie Z, Song L, Zhang P, Liu C, Liu J. A 1064 nm excitable semiconducting polymer nanoparticle for photoacoustic imaging of gliomas. Nanoscale 2019;11:7754-60. [PMID: 30949651 DOI: 10.1039/c9nr00552h] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 6.7] [Reference Citation Analysis]
108 Pigeon H, Pérès EA, Truillet C, Jego B, Boumezbeur F, Caillé F, Zinnhardt B, Jacobs AH, Le Bihan D, Winkeler A. TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma. Neuro Oncol 2019;21:755-64. [PMID: 30721979 DOI: 10.1093/neuonc/noz029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
109 Thon N, Kreth FW, Tonn JC. The role of surgery in grade II/III oligodendroglial tumors. CNS Oncol 2015;4:317-23. [PMID: 26478133 DOI: 10.2217/cns.15.26] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
110 Miller-Thomas MM, Benzinger TL. Neurologic Applications of PET/MR Imaging. Magn Reson Imaging Clin N Am 2017;25:297-313. [PMID: 28390530 DOI: 10.1016/j.mric.2016.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
111 Fuenfgeld B, Mächler P, Fischer DR, Esposito G, Rushing EJ, Kaufmann PA, Stolzmann P, Huellner MW. Reference values of physiological 18F-FET uptake: Implications for brain tumor discrimination. PLoS One 2020;15:e0230618. [PMID: 32302317 DOI: 10.1371/journal.pone.0230618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Jacobson O, Chen X. Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev 2013;65:1214-56. [PMID: 24064460 DOI: 10.1124/pr.113.007625] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
113 Norikane T, Mitamura K, Yamamoto Y, Maeda Y, Tanaka K, Hatakeyama T, Miyake K, Toyohara J, Nishiyama Y. Correlation of 4'-[methyl-11C]-thiothymidine PET with Gd-enhanced and FLAIR MRI in patients with newly diagnosed glioma. EJNMMI Res 2021;11:42. [PMID: 33929642 DOI: 10.1186/s13550-021-00785-8] [Reference Citation Analysis]
114 Mattoli MV, Trevisi G, Scolozzi V, Capotosti A, Cocciolillo F, Marini I, Mare V, Indovina L, Caulo M, Saponiero A, Balducci M, Taralli S, Calcagni ML. Dynamic 11C-Methionine PET-CT: Prognostic Factors for Disease Progression and Survival in Patients with Suspected Glioma Recurrence. Cancers (Basel) 2021;13:4777. [PMID: 34638262 DOI: 10.3390/cancers13194777] [Reference Citation Analysis]
115 Patel B, Yang PH, Kim AH. The effect of thermal therapy on the blood-brain barrier and blood-tumor barrier. Int J Hyperthermia 2020;37:35-43. [PMID: 32672118 DOI: 10.1080/02656736.2020.1783461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
116 Arora G, Sharma P, Sharma A, Mishra AK, Hazari PP, Biswas A, Garg A, Aheer D, Kumar R. 99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI. Clin Nucl Med 2018;43:e132-8. [PMID: 29517540 DOI: 10.1097/RLU.0000000000002036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
117 Suchorska B, Albert NL, Tonn J. Role of amino-tracer PET for decision-making in neuro-oncology. Current Opinion in Neurology 2018;31:720-6. [DOI: 10.1097/wco.0000000000000616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
118 Wang H, Huang Z, Zhang Q, Gao D, OuYang Z, Liang D, Liu X, Yang Y, Zheng H, Hu Z. Technical note: A preliminary study of dual-tracer PET image reconstruction guided by FDG and/or MR kernels. Med Phys 2021. [PMID: 34252216 DOI: 10.1002/mp.15089] [Reference Citation Analysis]
119 Kamson DO, Juhász C, Buth A, Kupsky WJ, Barger GR, Chakraborty PK, Muzik O, Mittal S. Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates. J Neurooncol 2013;112:121-32. [PMID: 23299463 DOI: 10.1007/s11060-013-1043-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
120 Gempt J, Bette S, Ryang YM, Buchmann N, Peschke P, Pyka T, Wester HJ, Förster S, Meyer B, Ringel F. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. Eur J Radiol 2015;84:955-62. [PMID: 25748815 DOI: 10.1016/j.ejrad.2015.01.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
121 Wright E, Amankwah EK, Winesett SP, Tuite GF, Jallo G, Carey C, Rodriguez LF, Stapleton S. Incidentally found brain tumors in the pediatric population: a case series and proposed treatment algorithm. J Neurooncol 2019;141:355-61. [DOI: 10.1007/s11060-018-03039-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
122 Niyazi M, Schnell O, Suchorska B, Schwarz SB, Ganswindt U, Geisler J, Bartenstein P, Kreth FW, Tonn JC, Eigenbrod S, Belka C, la Fougère C. FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 2012;104:78-82. [PMID: 22673727 DOI: 10.1016/j.radonc.2012.04.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
123 Tarkkonen A, Rissanen E, Tuokkola T, Airas L. Utilization of PET imaging in differential diagnostics between a tumefactive multiple sclerosis lesion and low-grade glioma. Mult Scler Relat Disord 2016;9:147-9. [PMID: 27645363 DOI: 10.1016/j.msard.2016.07.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
124 Albrecht V, Richter A, Pfeiffer S, Gebauer M, Lindner S, Gieser E, Schüller U, Schichor C, Gildehaus FJ, Bartenstein P, Tonn JC, Skerra A, Glass R. Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas. Int J Cancer 2016;138:1269-80. [PMID: 26421425 DOI: 10.1002/ijc.29874] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
125 Chow D, Chang P, Weinberg BD, Bota DA, Grinband J, Filippi CG. Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. American Journal of Roentgenology 2018;210:30-8. [DOI: 10.2214/ajr.17.18754] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
126 Adhikari A, Singh P, Mahar KS, Adhikari M, Adhikari B, Zhang MR, Tiwari AK. Mapping of Translocator Protein (18 kDa) in Peripheral Sterile Inflammatory Disease and Cancer through PET Imaging. Mol Pharm 2021;18:1507-29. [PMID: 33645995 DOI: 10.1021/acs.molpharmaceut.1c00002] [Reference Citation Analysis]
127 Banati RB, Wilcox P, Xu R, Yin G, Si E, Son ET, Shimizu M, Holsinger RMD, Parmar A, Zahra D, Arthur A, Middleton RJ, Liu GJ, Charil A, Graeber MB. Selective, high-contrast detection of syngeneic glioblastoma in vivo. Sci Rep 2020;10:9968. [PMID: 32561881 DOI: 10.1038/s41598-020-67036-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Holzgreve A, Brendel M, Gu S, Carlsen J, Mille E, Böning G, Mastrella G, Unterrainer M, Gildehaus FJ, Rominger A, Bartenstein P, Kälin RE, Glass R, Albert NL. Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches. Front Neurosci 2016;10:260. [PMID: 27378835 DOI: 10.3389/fnins.2016.00260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
129 Bonm AV, Ritterbusch R, Throckmorton P, Graber JJ. Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review. J Neuroimaging 2020;30:139-45. [PMID: 31925884 DOI: 10.1111/jon.12687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
130 Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020;20:57-70. [PMID: 31806884 DOI: 10.1038/s41568-019-0226-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
131 Panosyan EH, Lasky JL, Lin HJ, Lai A, Hai Y, Guo X, Quinn M, Nelson SF, Cloughesy TF, Nghiemphu PL. Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. J Neurooncol 2016;128:57-66. [PMID: 26922345 DOI: 10.1007/s11060-016-2073-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
132 Walter F, la Fougère C, Belka C, Niyazi M. Technical Issues of [(18)F]FET-PET Imaging for Radiation Therapy Planning in Malignant Glioma Patients - A Review. Front Oncol 2012;2:130. [PMID: 23061046 DOI: 10.3389/fonc.2012.00130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
133 Katsanos AH, Alexiou GA, Fotopoulos AD, Jabbour P, Kyritsis AP, Sioka C. Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading: A Meta-analysis. Clin Nucl Med 2019;44:864-9. [DOI: 10.1097/rlu.0000000000002654] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 8.3] [Reference Citation Analysis]
134 Kardan A, Satter M. Advanced Methionine Positron-Emission Tomography Imaging for Brain Tumor Diagnosis, Surgical Planning, and Treatment. Handbook of Neuro-Oncology Neuroimaging. Elsevier; 2016. pp. 371-84. [DOI: 10.1016/b978-0-12-800945-1.00034-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Khangembam BC, Singhal A, Kumar R, Bal C. Tc-99m Glucoheptonate Single Photon Emission Computed Tomography-Computed Tomography for Detection of Recurrent Glioma: A Prospective Comparison with N-13 Ammonia Positron Emission Tomography-Computed Tomography. Indian J Nucl Med 2019;34:107-17. [PMID: 31040521 DOI: 10.4103/ijnm.IJNM_164_18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Lombardi G, Barresi V, Castellano A, Tabouret E, Pasqualetti F, Salvalaggio A, Cerretti G, Caccese M, Padovan M, Zagonel V, Ius T. Clinical Management of Diffuse Low-Grade Gliomas. Cancers (Basel) 2020;12:E3008. [PMID: 33081358 DOI: 10.3390/cancers12103008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
137 Heiss W. Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences. Eur J Neurol 2017;24:1255. [DOI: 10.1111/ene.13385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
138 Mittra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, Iagaru AH, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies. PLoS One 2016;11:e0148628. [PMID: 26890637 DOI: 10.1371/journal.pone.0148628] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
139 Saadatpour Z, Rezaei A, Ebrahimnejad H, Baghaei B, Bjorklund G, Chartrand M, Sahebkar A, Morovati H, Mirzaei HR, Mirzaei H. Imaging techniques: new avenues in cancer gene and cell therapy. Cancer Gene Ther. 2017;24:1-5. [PMID: 27834357 DOI: 10.1038/cgt.2016.61] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
140 Maralani PJ, Das S, Mainprize T, Phan N, Bharatha A, Keith J, Munoz DG, Sahgal A, Symons S, Ironside S, Faraji-dana Z, Eilaghi A, Chan A, Alcaide-leon P, Shearkhani O, Jakubovic R, Atenafu EG, Zaharchuk G, Mikulis D. Hypoxia Detection in Infiltrative Astrocytoma: Ferumoxytol-based Quantitative BOLD MRI with Intraoperative and Histologic Validation. Radiology 2018;288:821-9. [DOI: 10.1148/radiol.2018172601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
141 Suchorska B, Albert NL, Bauer EK, Tonn JC, Galldiks N. The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. Q J Nucl Med Mol Imaging 2018;62:267-71. [PMID: 29696947 DOI: 10.23736/S1824-4785.18.03090-X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
142 Ryan ER, Sofocleous CT, Schöder H, Carrasquillo JA, Nehmeh S, Larson SM, Thornton R, Siegelbaum RH, Erinjeri JP, Solomon SB. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013;268:288-295. [PMID: 23564714 DOI: 10.1148/radiol.13121462] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 8.2] [Reference Citation Analysis]
143 Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Pöschl J, Schüller U, Schichor C, Thon N, Tonn JC. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med 2015;56:347-53. [PMID: 25635133 DOI: 10.2967/jnumed.114.149120] [Cited by in Crossref: 74] [Cited by in F6Publishing: 56] [Article Influence: 10.6] [Reference Citation Analysis]
144 Valtorta S, Salvatore D, Rainone P, Belloli S, Bertoli G, Moresco RM. Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance. Int J Mol Sci 2020;21:E5631. [PMID: 32781585 DOI: 10.3390/ijms21165631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
145 Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Götz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu AL. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).BMC Cancer. 2016;16:769. [PMID: 27716184 DOI: 10.1186/s12885-016-2806-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
146 Navarria P, Reggiori G, Pessina F, Ascolese AM, Tomatis S, Mancosu P, Lobefalo F, Clerici E, Lopci E, Bizzi A, Grimaldi M, Chiti A, Simonelli M, Santoro A, Bello L, Scorsetti M. Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiother Oncol 2014;112:425-9. [PMID: 25308182 DOI: 10.1016/j.radonc.2014.09.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
147 Niyazi M, Jansen N, Ganswindt U, Schwarz SB, Geisler J, Schnell O, Büsing K, Eigenbrod S, la Fougère C, Belka C. Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET. J Neurooncol 2012;110:389-95. [DOI: 10.1007/s11060-012-0980-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
148 Trikalinos NA, Nihashi T, Evangelou E, Terasawa T. Positron emission tomography (PET) for prediction of glioma histology: protocol for an individual-level data meta-analysis of test performance. BMJ Open 2018;8:e020187. [PMID: 29455169 DOI: 10.1136/bmjopen-2017-020187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
149 Khalilov VS, Kholin AA, Gazdieva KS, Kislyakov AN, Zavadenko NN. [Features of the neuroradiological picture of ganglioglioma on the example of 20 clinical cases]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:90-8. [PMID: 33340303 DOI: 10.17116/jnevro202012011190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Blanc-Durand P, Van Der Gucht A, Verger A, Langen KJ, Dunet V, Bloch J, Brouland JP, Nicod-Lalonde M, Schaefer N, Prior JO. Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas. PLoS One 2018;13:e0199379. [PMID: 29953478 DOI: 10.1371/journal.pone.0199379] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
151 Soni N, Ora M, Mohindra N, Menda Y, Bathla G. Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature. AJNR Am J Neuroradiol 2020;41:1550-7. [PMID: 32855194 DOI: 10.3174/ajnr.A6685] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Murphy KR, Aycock KN, Hay AN, Rossmeisl JH, Davalos RV, Dervisis NG. High-frequency irreversible electroporation brain tumor ablation: exploring the dynamics of cell death and recovery. Bioelectrochemistry 2021;144:108001. [PMID: 34844040 DOI: 10.1016/j.bioelechem.2021.108001] [Reference Citation Analysis]
153 Ambady P, Bettegowda C, Holdhoff M. Emerging methods for disease monitoring in malignant gliomas. CNS Oncol 2013;2:511-22. [PMID: 25054821 DOI: 10.2217/cns.13.44] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
154 Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, Bartenstein P, Belka C, Kreth FW, Fougère CL. [ 18 F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma. Mol Imaging 2013;12:7290.2012.00027. [DOI: 10.2310/7290.2012.00027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
155 Jandial R, Neman J, Lim PP, Tamae D, Kowolik CM, Wuenschell GE, Shuck SC, Ciminera AK, De Jesus LR, Ouyang C, Chen MY, Termini J. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. Int J Mol Sci 2018;19:E406. [PMID: 29385725 DOI: 10.3390/ijms19020406] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
156 Thon N, Tonn JC, Kreth FW. The surgical perspective in precision treatment of diffuse gliomas. Onco Targets Ther 2019;12:1497-508. [PMID: 30863116 DOI: 10.2147/OTT.S174316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
157 Zhu L, Guo N, Li Q, Ma Y, Jacboson O, Lee S, Choi HS, Mansfield JR, Niu G, Chen X. Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe. Theranostics 2012;2:746-56. [PMID: 22916074 DOI: 10.7150/thno.4762] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
158 Cheung YY, Nickels ML, Tang D, Buck JR, Manning HC. Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer. Bioorg Med Chem Lett 2014;24:4466-71. [PMID: 25172419 DOI: 10.1016/j.bmcl.2014.07.091] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
159 Verburg N, Hoefnagels FWA, Barkhof F, Boellaard R, Goldman S, Guo J, Heimans JJ, Hoekstra OS, Jain R, Kinoshita M, Pouwels PJW, Price SJ, Reijneveld JC, Stadlbauer A, Vandertop WP, Wesseling P, Zwinderman AH, De Witt Hamer PC. Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. AJNR Am J Neuroradiol 2017;38:1884-91. [PMID: 28882867 DOI: 10.3174/ajnr.A5368] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
160 Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, Walter F, Kunz WG, Rosenschöld PMA, Jeraj R, Albert NL, Grosu AL, Niyazi M, Bartenstein P, Belka C. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol 2020;15:88. [PMID: 32317029 DOI: 10.1186/s13014-020-01519-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
161 Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J 2012;18:26-31. [PMID: 22290254 DOI: 10.1097/PPO.0b013e318244d7c8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
162 Alfonso JCL, Talkenberger K, Seifert M, Klink B, Hawkins-Daarud A, Swanson KR, Hatzikirou H, Deutsch A. The biology and mathematical modelling of glioma invasion: a review. J R Soc Interface 2017;14:20170490. [PMID: 29118112 DOI: 10.1098/rsif.2017.0490] [Cited by in Crossref: 86] [Cited by in F6Publishing: 66] [Article Influence: 21.5] [Reference Citation Analysis]
163 Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med 2015;7:274ra17-274ra17. [DOI: 10.1126/scitranslmed.aaa1009] [Cited by in Crossref: 175] [Cited by in F6Publishing: 158] [Article Influence: 29.2] [Reference Citation Analysis]
164 Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B. Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques. AJNR Am J Neuroradiol 2020;41:10-20. [PMID: 31857322 DOI: 10.3174/ajnr.A6358] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
165 Heiss WD. [PET in gliomas. Overview of current studies]. Nuklearmedizin 2014;53:163-71; quiz N32. [PMID: 24853278 DOI: 10.3413/Nukmed-0662-14-04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
166 Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, Holland EC, Galbán CJ, Ross BD. DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One 2012;7:e35857. [PMID: 22536446 DOI: 10.1371/journal.pone.0035857] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
167 Shi X, Liu Y, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med 2013;38:522-6. [PMID: 23698463 DOI: 10.1097/RLU.0b013e318295298d] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
168 Ebrahimpour-koujan S, Shayanfar M, Benisi-kohansal S, Mohammad-shirazi M, Sharifi G, Esmaillzadeh A. Adherence to low carbohydrate diet in relation to glioma: A case-control study. Clinical Nutrition 2019;38:2690-5. [DOI: 10.1016/j.clnu.2018.11.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]